Related Experiment Video
Updated: Oct 26, 2025
10:21
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
10.1K
Pediatric Myeloproliferative Neoplasms.
Farah El-Sharkawy1, Elizabeth Margolskee2
1Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Clinics in Laboratory Medicine
|July 26, 2021
Summary
Pediatric myeloproliferative neoplasms are rare and challenging to diagnose. This review covers diagnosis, prognosis, and therapy for childhood chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, and primary myelofibrosis.
Area of Science:
- Hematology
- Pediatric Oncology
Background:
- Myeloproliferative neoplasms (MPNs) are a group of disorders that can occur in children.
- Diagnosis, prognosis, and therapy for pediatric MPNs are not well-established.
- This review focuses on specific MPNs in children.
Purpose of the Study:
- To provide a comprehensive overview of pediatric myeloproliferative neoplasms.
- To discuss the diagnostic challenges, prognostic factors, and therapeutic strategies for these conditions in children.
Main Methods:
- Literature review focusing on pediatric myeloproliferative neoplasms.
- Synthesis of current knowledge on diagnosis, prognosis, and therapy.
- Discussion of specific MPN subtypes in the pediatric population.
Main Results:
- Pediatric MPNs can present unique diagnostic and therapeutic challenges.
- Specific considerations for chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, and primary myelofibrosis in children are highlighted.
- Limited research exists specifically for pediatric MPNs.
Conclusions:
- Early diagnosis and tailored therapy are crucial for improving outcomes in pediatric MPNs.
- Further research is needed to better understand and manage these rare conditions in children.
- This review serves as a resource for clinicians managing pediatric MPNs.
Keywords:
Chronic myeloid leukemiaEssential thrombocythemiaMyeloproliferative neoplasmsPediatricsPolycythemia veraPrimary myelofibrosisMore Related Videos
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
3.6K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.6K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
47
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
47
02:23Abnormal Proliferation
4.8K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
45
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
45
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
57
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
57
01:22Bone Marrow Sampling and Transplants
588
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
588